OmniAb, Inc. (NASDAQ:OABI) CEO Sells $135,467.64 in Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 41,811 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $135,467.64. Following the completion of the sale, the chief executive officer now directly owns 3,749,639 shares of the company’s stock, valued at $12,148,830.36. This represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

OmniAb Trading Down 0.6 %

NASDAQ:OABI opened at $3.20 on Thursday. The company has a market capitalization of $451.90 million, a P/E ratio of -5.16 and a beta of -0.10. The firm has a 50-day moving average price of $3.68 and a two-hundred day moving average price of $4.06. OmniAb, Inc. has a twelve month low of $3.16 and a twelve month high of $6.55.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. CWC Advisors LLC. purchased a new stake in OmniAb in the 3rd quarter valued at approximately $54,000. Walleye Capital LLC purchased a new stake in shares of OmniAb in the third quarter valued at $61,000. Intech Investment Management LLC purchased a new stake in shares of OmniAb in the third quarter valued at $70,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of OmniAb by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after acquiring an additional 8,909 shares during the last quarter. Finally, Palumbo Wealth Management LLC increased its position in OmniAb by 12.5% during the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock worth $104,000 after purchasing an additional 2,744 shares in the last quarter. 72.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OABI has been the subject of several research analyst reports. Benchmark reiterated a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.